Publication of new Aveed data in Journal of Clinical Pharmacology; data evaluates dosing flexibility in men with hypogonadism.
The objective of this population PK analysis was to assess the potential impact of a more frequent dose regimen of testosterone undecanoate (8 weeks vs. 10 weeks) on exposure parameters of clinical interest.
The current FDA-approved recommended dose of Aveed is 3 mL (750 mg) injected intermuscularly, followed by 3 mL (750 mg) injected after 4 weeks, then 3 mL (750 mg) injected every 10 weeks thereafter. The findings from this PK model and simulation were published in The Journal of Clinical Pharmacology.
See-"Population Pharmacokinetic Modeling and Simulations to Evaluate a Potential Dose Regimen of Testosterone Undecanoate in Hypogonadal Males."-Alexander W. Pastuszak MD, PhD, Mark Bush PhD, Laura Curd MS, Saji Vijayan MBBS, D.Diab, Tony Priestley PhD, Qinfang Xiang PhD, Yiqun Hu MD, PhD First published: 16 July 2021 https://doi.org/10.1002/jcph.1939.
Related news and insights
Scynexis, Inc. announced that the FDA has approved a second indication for Bexafemme (ibrexafungerp tablets) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC)
Eli Lilly and Company has announced that donanemab met all primary and secondary endpoints for the 6-month primary outco me analysis in the Phase III TRAILBLAZER-ALZ 4 study , providing the first active comparator data on amyloid plaque clearance in patients with early symptomatic Alzheimer's disease treated with amyloid-targeting therapies